29th-31st January 2018

Paris, France

Workshop A
Tuesday 24th January, 2017

09.00 - 12.00
Past, Present and Future Applications: How to use FMT to Fight Disease?
Workshop Leader: Emilie Plantamura, Clinical Project Manager, MaaT Pharma Workshop Leader: Harry Sokol, Professor of Gastroenterology, Assistance Publique-Hopitaux De Paris

Fecal Microbiota Transfer (FMT) is a procedure that has shown strong effectiveness in treating C.Difficile. Researchers are also exploring FMT’s role for treating other diseases, such as IBD and multidrug-resistant bacteria. This interactive workshop will give you the opportunity to learn from two highly experienced clinicians and a leading European Biotech who will address the important considerations in FMT that must be evaluated for global adoption.

The session will be split into three therapeutic applications of FMT:

  • Harry Sokol, MD, PhD, will talk about FMT as a therapy for IBD
  • Emilie Plantamura, Pharm D, PhD will explore MaaT Pharma’s approach to autologous FMT in fighting MDRB and other opportunistic pathogens following antimicrobial and chemotherapy treatment

Emilie Plantamura, Clinical Project Manager, MaaT Pharma

emilie-plantamura

Harry Sokol, Professor of Gastroenterology, Assistance Publique-Hopitaux De Paris

harry-sokol

Workshop B
Tuesday 24th January, 2017

13.00 - 16.00
Pharmaceutical OR Consumer Product? Re-Writing the Rules for Microbiome Therapies
Workshop Leader: Larry Weiss, CMO, AOBiome Workshop Leader: Johan Vlieg, VP, Microbiome and Human Health Innovation, Chr. Hansen Workshop Leader: Mohan Iyer, Chief Business Officer, Second Genome, Inc.

While the number of published microbiome studies continues to rise at an exponential rate, few are well designed, adequately powered, and incorporate systems biology. Without a true systems approach, it is certainly difficult to make sense of much of the microbiome data, much less rest on such data for expensive product development decisions. Furthermore, potential breakthrough microbiome therapies face serious translational hurdles if the key efficacy data arises solely from animal models. Thus, the industry needs to break old paradigms and re-write the rule books in order to succeed.

Executives of all types (science, business, regulatory) who are involved in a microbiome development program must consider four core strategic questions:

  • Scientific Activities – What are the best methods to generate truly actionable microbiome data that can be translated into a product?
  • Clinical Activities – How can we obtain decisive human data as quickly as possible? • Regulatory Activities – Which regulatory path can allow developers to get things done?
  • Financial Activities – Which avenue will maximize shareholder value?

This interactive workshop will give you the opportunity to engage with three highly experienced microbiome specialists who visualise the microbiome from different perspectives. Will next-gen probiotics be the best solution? Will pharmaceutical drugs supplant consumer products? Short term versus long term?If we were to rewrite all the rules, what would this look like?

Larry Weiss, CMO, AOBiome

larry-weiss

Johan Vlieg, VP, Microbiome and Human Health Innovation, Chr. Hansen

johan-vlieg

Mohan Iyer, Chief Business Officer, Second Genome, Inc.

mohan-iyer